OakChart

Organogenesis Holdings Inc

ORGOHealthcare·Drug Manufacturers - Specialty & Generic·USA·Micro·NASD·Nov 11 • 2:37 PM ET

1.01+0.07 (8.00%)
2026-11-11 20:38 CET
Market cap
121.39 USD m
Revenue, TTM
352.05 USD m
Net income, TTM
-153.15 USD m
Free cash flow, TTM
-0.06 USD m
EPS diluted, TTM
-1.20
P/E
-
Compare

Price

ORGO against its 20, 50 and 200-day averages
2050200miss
1.002.003.004.002.4M4.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ORGOclose 1.0120-day 0.9250-day 1.22200-day 2.251.0152w low

85.7% under the 52-week high of 7.08 on 11 Nov 2025. 52-week low 0.73 on 2 Nov 2026. Last 15 sessions, 43.8% high to low

Profile

ORGO
52-week range, 4% of the way up
0.737.08

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

IndexRUT
Employees854
IPOJan 05, 2017
Beta1.44
ATR, 14d0.09
Rel volume0.75
Short float21.75%
Insider own44.68%
Inst own50.96%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap131.10M
Enterprise Value317.13M
Income-153.15M
Sales352.05M
Book/sh0.92
Cash/sh0.17
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees854
IPOJan 05, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S0.37
P/B1.09
P/C6.10
P/FCF-
EV/EBITDA-
EV/Sales0.90
Quick Ratio2.76
Current Ratio3.32
Debt/Eq0.25
LT Debt/Eq0.21
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.20
EPS next Y-0.44
EPS next Q-0.11
EPS this Y-575.08%
EPS next Y68.00%
EPS next 5Y-
EPS past 3/5Y9.43% -0.14%
Sales past 3/5Y7.76% 10.77%
EPS Y/Y TTM-1171.44%
Sales Y/Y TTM-24.33%
EPS Q/Q-328.83%
Sales Q/Q-69.87%
EarningsNov 05 AMC
EPS/Sales Surpr.-41.49% -12.67%

Ownership

Insider Own44.68%
Insider Trans0.00%
Inst Own50.96%
Inst Trans4.06%
ROA-30.81%
ROE-41.73%
ROIC-42.57%
Gross Margin56.34%
Oper. Margin-21.69%
Profit Margin-43.50%
SMA209.90%
SMA50-17.00%
SMA200-55.13%
Trades-

Technical

Shs Outstand129.79M
Shs Float71.80M
Short Float21.75%
Short Ratio18.77
Short Interest15.61M
52W High7.08 -85.73%
52W Low0.73 38.36%
Volatility13.57% 10.06%
ATR (14)0.09
RSI (14)49.47
Beta1.44
Rel Volume0.75
Avg Volume831.80K
Volume495,284

Performance

Perf Week16.09%
Perf Month-16.53%
Perf Quarter-42.61%
Perf Half Y-62.59%
Perf YTD-80.50%
Perf Year-84.46%
Perf 3Y-53.88%
Perf 5Y-90.85%
Perf 10Y-
Recom3.00
Target Price2.00
Prev Close0.94
Price1.01
Change %8.00%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
May 28, 2026InitiatedTTruistHold$3+197.0%
May 08, 2026DowngradeBBTIG ResearchBuy → Neutral
Jun 28, 2024InitiatedLLake StreetBuy$5+395.0%
Feb 07, 2024InitiatedCCantor FitzgeraldOverweight$5+395.0%
Jun 15, 2023InitiatedMMorgan StanleyEqual-Weight$5+395.0%
May 24, 2023UpgradeBBTIG ResearchNeutral → Buy$10+890.1%
Nov 10, 2022DowngradeBBTIG ResearchBuy → Neutral
Aug 10, 2022DowngradeOOppenheimerOutperform → Perform
Jan 10, 2020InitiatedSSVB LeerinkOutperform$9+791.1%
Aug 26, 2019ResumedCCredit SuisseOutperform$9 → $10+890.1%

Peers

Mkt cap
TickerCompanyMkt cap
MDXGMimedx Group Inc495.30M
ANIKAnika Therapeutics Inc187.25M
IARTIntegra Lifesciences Holdings Corp1.17B
RCELAVITA Medical Inc432.22M
SNNSmith & Nephew plc ADR13.00B
BVSBioventus Inc933.72M
SMTISanara MedTech Inc291.41M
VCELVericel Corp3.00B
SNWVSanuwave Health Inc14.88M
CELUCelularity Inc24.21M

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Leibowitz Arthur SDirectorMar 09 '26Buy2.685,00013,405291,014Mar 11 09:45 PM
Driscoll Michael JosephDirectorMar 09 '26Buy2.6710,00026,688225,707Mar 11 05:45 PM
NUSSDORF GLENN HDirectorDec 16 '25Sale5.14200,0001,027,0602,565,591Dec 18 04:19 PM
Glenn NussdorfDirectorDec 16 '25Proposed Sale5.11200,0001,021,241Dec 16 04:32 PM
NUSSDORF GLENN HDirectorNov 26 '25Sale5.29187,957994,2932,765,591Nov 26 06:24 PM
NUSSDORF GLENN HDirectorNov 24 '25Sale5.34100,000534,0002,965,591Nov 26 06:24 PM
NUSSDORF GLENN HDirectorNov 25 '25Sale5.3012,04363,8282,953,548Nov 26 06:24 PM
Glenn NussdorfDirectorNov 25 '25Proposed Sale5.40200,0001,080,000Nov 25 04:56 PM
Glenn NussdorfDirectorNov 24 '25Proposed Sale5.34100,000534,379Nov 24 03:44 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFATU.S. Targeted Value Portfolio-ETF Class SharesAUM: 14.47B
DFSVUS Small Cap Value Portfolio ETF Class SharesAUM: 8.52B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M

News

latest 14 of 200
  • Organogenesis Shows Sequential Repair, But A Third Guidance Cut, An FDA Setback, And A $26.9 Million Cash Balance Dominate The Quarter (Earnings Whispers)
  • Organogenesis: Q3 Earnings Snapshot (Associated Press)
  • Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPlyAM for Hard-to-Heal Diabetic Foot Ulcers (GlobeNewswire)
  • Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026 (GlobeNewswire)
  • These beaten-down stocks could bounce back in January, if history is any guide (MarketWatch) +5.71%
  • Organogenesis: Q2 Earnings Snapshot (Associated Press) -22.82%
  • Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity in the Most Challenging and Complex Venous Leg Ulcers (GlobeNewswire) +6.69%
  • Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 (GlobeNewswire)
  • Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu for the Management of Symptomatic Knee Osteoarthritis (GlobeNewswire) +5.08%
  • The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts (PR Newswire) -5.08%
  • Organogenesis: Q1 Earnings Snapshot (Associated Press) -6.32%
  • Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.248-0.175-0.25045.5052.102
2026Q22026-08-06-0.714-0.350-0.77243.7654.272
2026Q12026-05-07-0.366-0.290-0.43936.2543.261
2025Q42026-02-260.3100.2150.266225.07172.652
2025Q32025-11-060.1230.0650.111150.86134.122
2025Q22025-08-07-0.063-0.050-0.096101.01103.413
2025Q12025-05-08-0.170-0.038-0.17186.6990.774
2024Q42025-02-270.040-0.0110.058126.66109.614
2024Q32024-11-120.090-0.0200.092115.18108.833
2024Q22024-08-08-0.1300.005-0.129130.23121.34
2024Q12024-05-09-0.015-0.023-0.016109.98101.073
2023Q42024-02-290.0190.008-0.00499.65109.063
2023Q32023-11-090.0360.0110.024108.53111.432
2023Q22023-08-090.0460.0310.040117.32115.092
2023Q12023-05-10-0.003-0.020-0.023107.6495.521
2022Q42023-03-010.0710.0500.057115.52122.41

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-0.923--0.935193.4-
2019FY-0.440-0.490-0.443260.98256.75
2020FY0.1700.1150.155338.3336.75
2021FY0.7580.4160.705468.06463.9
2022FY0.2010.1200.117450.89458.8
2023FY0.0980.0650.037433.14441.7
2024FY-0.010-0.0730.007482.04465.62
2025FY0.2890.1520.150563.03511.07
2026FY--1.375--187.82
2027FY--0.440--234.65
2028FY--0.350--260.31

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0620261.4057.9064.91
2026Q4S2026-10-2120062.9958.9067.09
2026Q4S2026-08-1920262.9958.9067.09
2026Q4S2026-08-0720263.0058.9067.10
2026Q4S2026-07-22200110.47108.72112.21
2026Q4S2026-06-09201110.47108.72112.21
2026Q4S2026-05-27201110.46108.7112.21
2026Q4S2026-05-08101108.7108.7108.7
2026Q4S2026-03-25101148.28148.28148.28
2026Q4S2026-03-24101148.3148.3148.3
2026Q4S2026-02-27101148.28148.28148.28
2026Q4S2026-01-21200174.04163.6184.49
2026Q4S2025-12-25211174.04163.6184.49
2026Q4S2025-12-22211174.05163.6184.5

Estimate history

EPS, annual-0.48-0.935-0.4430.1550.7050.1170.0370.0070.154-1.1998
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0920.058-0.171-0.0960.1110.266-0.439-0.772-0.254
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0193.449260.981338.298467.359450.893433.14482.043564.169352.05
Period201720182019202020212022202320242025TTM
Sales, quarterly115.177126.65686.693101.005150.864225.60737.22843.75545.457
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual9.68391.261104.871127.732128.68130.919131.316125.73126.952129.794
Period201720182019202020212022202320242025MRQ
Shares, quarterly132.577125.73126.854126.854126.911126.952128.675128.675129.794
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue352.05564.17482.04433.14450.89467.36338.30260.98193.45
Cost of Goods Sold Incl. D&A153.69164.46132.91123.35113.40118.8092.4585.3868.81
Gross Profit198.36399.71349.14309.79337.49348.56245.85175.60124.64
Selling, General and Administrative Excl. Other274.73343.32319.19286.89299.07259.56216.10205.06168.35
Research and Development51.7044.5450.2744.3839.7630.7420.0914.8010.74
Other Operating Expense0.000.008.216.589.6512.083.050.000.00
Operating Income-76.3756.3821.7316.3228.7776.9226.70-29.46-43.71
Interest Expense--1.542.192.017.2411.289.0010.85
Unusual Expense9.7111.6923.023.802.276.59-2.251.8610.41
Net Income Before Taxes-85.5546.97-2.8110.3920.2863.0917.76-40.30-64.75
Income Taxes49.809.94-3.675.454.75-31.120.530.150.08
Consolidated Net Income-135.3537.030.864.9515.5394.2017.23-40.45-64.83
Net Income From Continuing Operations-135.3537.030.864.9515.5394.2017.23-40.45-64.83
Net Income-153.1520.020.864.9515.5394.2017.23-41.10-64.83
EPS (Recurring)-1.130.220.130.060.130.740.14-0.43-0.83
EPS (Basic, Before Extraordinaries)-1.190.160.010.040.120.730.16-0.44-0.94
EPS (Diluted)-1.200.150.010.040.120.700.15-0.44-0.94
EBITDA-43.9583.3247.1139.7746.8093.6034.88-20.03-36.74
Non-Operating Income (Expense)0.602.280.020.06-4.21-0.010.100.010.23
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.9210.518.367.115.182.820.680.680.85
Price To Earnings Ratio---41.825.9013.0053.40--
Price To Sales Ratio0.501.200.871.250.792.642.481.713.64
Gross Margin56.3470.8572.4371.5274.8574.5872.6767.2964.43
Operating Margin-21.699.994.513.776.3816.467.89-11.29-22.60
Net Margin-43.503.550.181.143.4420.165.09-15.75-33.51
Shares Outstanding129.79126.95125.73131.32130.92128.68127.73104.8791.26
Market Capitalization121.39121.39402.32540.05352.161,188.67943.40499.00502.12

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue45.4643.7637.23225.61150.86101.0086.69126.66
Cost of Goods Sold Incl. D&A28.3630.2638.1456.9343.2434.2830.0135.15
Gross Profit17.1013.49-0.91168.68107.6366.7256.6991.51
Selling, General and Administrative Excl. Other46.5960.5864.12103.4585.4677.3376.6578.97
Research and Development7.9618.3015.1610.2913.2210.3910.6411.53
Other Operating Expense0.000.000.000.000.000.000.002.33
Operating Income-29.49-47.08-65.0365.2322.16-10.62-19.9610.22
Interest Expense0.06-------
Unusual Expense0.003.913.861.941.441.966.78-
Net Income Before Taxes-29.62-50.88-68.4763.4321.16-11.83-25.7810.25
Income Taxes0.0145.39-15.3219.73-0.41-2.44-6.942.58
Consolidated Net Income-29.63-96.27-53.1643.7021.57-9.39-18.847.67
Net Income From Continuing Operations-29.63-96.27-53.1643.7021.57-9.39-18.847.67
Net Income-32.77-99.34-56.1635.1214.53-12.20-21.597.67
EPS (Recurring)-0.25-0.75-0.420.280.12-0.09-0.130.06
EPS (Basic, Before Extraordinaries)-0.25-0.77-0.440.280.11-0.10-0.170.06
EPS (Diluted)-0.25-0.77-0.440.270.11-0.10-0.170.06
EBITDA-23.03-40.49-52.6672.2429.15-3.96-13.6816.64
Non-Operating Income (Expense)-0.070.110.420.140.430.740.960.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.222.412.873.422.422.012.662.28
Price To Earnings Ratio--21.64---771.43-
Price To Sales Ratio0.500.680.591.211.191.081.190.88
Gross Margin37.6230.84-2.4674.7771.3466.0665.3972.25
Operating Margin-64.87-107.60-174.6928.9114.69-10.51-23.038.07
Net Margin-72.09-227.03-150.8515.579.63-12.08-24.916.06
Shares Outstanding129.79128.67128.67126.95126.91126.85126.85125.73
Market Capitalization121.39312.68304.88657.40535.34464.29547.90402.32

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments94.33136.15104.34103.29114.5384.8160.3721.410.13
Short Term Receivables217.45109.8682.0089.4582.4656.8039.3634.080.00
Inventories29.6326.2228.2524.7825.0227.8022.9213.320.00
Other Current Assets20.7813.7110.455.094.974.932.952.330.17
Total Current Assets362.19285.94225.04222.61226.98174.34125.6071.130.29
Net Property, Plant & Equipment159.46126.24156.35145.66128.3055.7947.1839.620.00
Total Investments and Advances0.000.000.000.000.000.000.000.00312.50
Long-Term Note Receivable-----0.000.560.48-
Intangible Assets37.9241.2444.6449.5654.4559.3946.3451.630.00
Deferred Tax Assets29.9639.4628.0030.0131.990.020.130.24-
Other Assets9.205.005.991.521.540.670.880.580.00
Total Assets598.73497.89460.02449.36443.26290.22220.69163.68312.79
Short Term Debt Incl. Current Port. of LT Debt18.649.1119.7116.2514.6420.293.0616.810.00
Accounts Payable31.9528.9130.7232.3329.3423.3828.3919.160.00
Other Current Liabilities49.5339.4530.0726.4538.7324.5528.4530.413.93
Total Current Liabilities100.1277.4880.5175.0282.7068.2259.8966.393.93
Long Term Debt63.4934.2099.64107.55117.6657.5491.2349.220.00
Provision for Risks Charges0.000.000.000.000.560.530.500.00-
Other Liabilities1.190.891.211.121.0022.1313.481.0310.85
Total Liabilities164.81112.57181.36183.69201.92148.41165.10116.6414.78
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value133.79122.420.000.000.000.000.000.00293.01
Common Equity300.13262.90278.66265.67241.34141.8155.5847.045.00
Total Shareholders Equity433.92385.32278.66265.67241.34141.8155.5847.04298.01
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity433.92385.32278.66265.67241.34141.8155.5847.04298.01
Total Liabilities & Stockholders Equity598.73497.89460.02449.36443.26290.22220.69163.68312.79
Book Value Per Share2.362.092.122.031.881.110.530.520.52
Tangible Book Value Per Share2.071.761.781.651.450.650.09-0.050.52
Full-Time Employees8548698621,030950910835700-
Price to Book Ratio1.011.521.941.374.916.589.0835.8018.96
Return on Assets6.750.181.093.4825.696.75-21.05-27.21-1.42
Return on Equity9.040.261.826.1249.1717.46-78.84-37.58-1.48
Return on Invested Capital7.440.211.314.1626.248.65-27.56-67.35-1.49
Quick Ratio3.323.352.442.642.442.151.710.870.07
Current Ratio3.623.692.802.972.742.562.101.070.07

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-135.3537.030.864.9515.5394.2017.23-40.45-64.83
Depreciation32.4326.9425.3723.4518.0316.688.189.436.98
Other Funds (Non Cash)39.7948.6047.5818.5823.4020.097.697.0519.33
Funds from Operations-17.55122.0763.1048.9958.9498.9933.22-23.86-38.34
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital27.85-132.38-48.89-18.07-34.08-37.01-27.76-9.67-22.40
Cash from Operating Activities10.30-10.3114.2130.9224.8661.985.47-33.53-60.74
Capital Expenditures-10.36-14.15-10.03-24.36-33.90-31.22-17.68-6.23-1.86
Net Assets From Acquisitions0.000.000.000.000.000.00-5.820.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources3.610.000.000.000.000.000.000.000.00
Cash from Investing Activities-6.75-14.15-10.03-24.36-33.90-31.22-23.50-6.23-1.86
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock1.430.1696.460.002.072.20-2.83-8.84-0.15
Repurchase of Common Pref Stock0.000.00-25.480.000.000.000.00-6.760.00
Sale of Common Pref Stock1.430.16121.940.002.072.20-2.83-2.08-0.15
Proceedsfrom Stock Options1.430.00120.690.000.000.00-5.66-2.97-0.27
Issuance or Reduction of Debt, Net-10.90-1.17-67.64-5.17-3.01-2.0148.8287.5681.79
Change in Long Term Debt-10.90-1.17-67.64-5.17-3.01-2.0148.8287.5681.79
Issuance of Long Term Debt0.000.000.000.000.0071.5574.73106.42104.48
Reduction of Long Term Debt-10.90-1.17-67.64-5.17-3.01-73.57-25.91-18.85-22.69
Net Financing Active Other Cash Flow-31.52-16.35-1.18-0.33-1.26-1.22-3.520.000.00
Other Financing Activities Uses-31.52-16.35-1.18-0.33-1.26-1.22-3.520.000.00
Cash from Financing Activities-40.98-17.3627.64-5.50-2.20-1.0442.4778.7381.64
Net Change in Cash-37.44-41.8231.811.05-11.2429.7224.4438.9719.05
Free Cash Flow-0.06-24.464.186.55-9.0430.76-12.21-39.51-62.60
Preferred Dividends (Cash Flow)--0.000.000.000.000.00-0.00
Price to Free Cash Flow--100.9082.85-40.15---
Deferred Taxes & Investment Tax Credit-9.50-10.722.011.98-31.980.110.110.19

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments21.4946.8492.1094.3364.3773.73
Short Term Receivables92.69100.94116.91217.45168.78120.38
Inventories26.6829.2828.4329.6339.5833.04
Other Current Assets17.2723.2431.0720.7827.0133.06
Total Current Assets158.13200.30268.50362.19299.75260.22
Net Property, Plant & Equipment146.41151.44157.82159.46111.36110.86
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets31.3431.7832.2137.9238.7239.56
Deferred Tax Assets0.000.0045.3329.9645.5941.75
Other Assets33.0322.9316.139.2014.418.73
Total Assets368.90406.45519.99598.73509.83461.13
Short Term Debt Incl. Current Port. of LT Debt9.319.319.7218.649.799.77
Accounts Payable22.4829.2928.6131.9540.2229.72
Income Tax Payable----0.180.17
Other Current Liabilities15.8618.3637.6849.5340.1326.17
Total Current Liabilities47.6556.9676.02100.1290.3265.84
Long Term Debt55.2057.6461.1463.4931.0231.05
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities3.313.711.491.192.513.02
Total Liabilities106.16118.31138.65164.81123.8599.91
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value143.00139.86136.79133.79130.85127.98
Common Equity119.74148.27244.56300.13255.13233.24
Total Shareholders Equity262.74288.13381.35433.92385.98361.22
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity262.74288.13381.35433.92385.98361.22
Total Liabilities & Stockholders Equity368.90406.45519.99598.73509.83461.13
Book Value Per Share0.921.151.902.362.011.84
Tangible Book Value Per Share0.680.911.652.071.711.53
Full-Time Employees---854--
Price to Book Ratio1.011.281.002.582.301.91
Return on Assets-30.81-19.400.556.750.21-1.82
Return on Equity-41.73-25.920.739.040.30-2.64
Return on Invested Capital-9.32-27.84-12.018.795.17-2.39
Quick Ratio2.763.003.163.322.883.45
Current Ratio3.323.523.533.623.323.95

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-29.63-96.27-53.1643.7021.57-9.39
Depreciation6.466.5912.377.016.996.66
Other Funds (Non Cash)11.684.606.7616.758.249.01
Funds from Operations-11.49-39.74-49.4083.0932.965.25
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-7.108.0970.53-43.67-29.88-38.12
Cash from Operating Activities-18.59-31.6521.1339.423.08-32.87
Capital Expenditures-1.47-1.10-3.15-4.65-2.23-3.64
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources3.610.000.000.000.000.00
Cash from Investing Activities2.15-1.10-3.15-4.65-2.23-3.64
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock1.430.000.000.000.130.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.430.000.000.000.130.00
Proceedsfrom Stock Options1.430.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.41-0.35-9.84-0.30-0.30-0.29
Change in Long Term Debt-0.41-0.35-9.84-0.30-0.30-0.29
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.41-0.35-9.84-0.30-0.30-0.29
Net Financing Active Other Cash Flow-4.48-12.15-10.37-4.51-10.040.00
Other Financing Activities Uses-4.48-12.15-10.37-4.51-10.040.00
Cash from Financing Activities-3.46-12.50-20.21-4.81-10.21-0.29
Net Change in Cash-19.91-45.26-2.2329.96-9.36-36.80
Free Cash Flow-20.06-32.7517.9834.770.84-36.51
Price to Free Cash Flow-15.0017.73---

Revenue breakdown

Grant2025: 1.14M
Product2024: 482.04M 2025: 563.03M
United States2024: 482.04M 2025: 564.17M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3021.75%15.6M71.8M836.57K
2026-10-1521.90%15.6M71.2M747.49K
2026-09-3021.07%15.0M71.2M752.79K
2026-09-1519.83%14.1M71.2M800.76K
2026-08-3120.01%14.2M71.2M805.64K
2026-08-1420.00%14.2M71.2M910.39K
2026-07-3118.70%13.3M71.2M1.02M
2026-07-1518.44%13.1M71.2M1.11M
2026-06-3019.39%13.8M71.2M1.54M
2026-06-1517.24%12.3M71.2M1.48M
2026-05-2919.72%13.3M67.4M1.51M
2026-05-1524.06%16.2M67.4M1.44M
2026-04-3028.39%15.9M55.8M1.21M
2026-04-1523.46%13.1M55.8M1.13M
2026-03-3123.31%12.8M54.9M702.83K
2026-03-1322.94%12.6M54.9M921.82K
2026-02-2722.98%12.6M54.9M1.01M
2026-02-1324.15%13.1M54.1M1.14M
2026-01-3022.08%13.0M59.1M1.81M
2026-01-1521.83%12.9M59.1M1.81M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.750.0517.83737.000.000.856-0.0350.000
call5.000.000.750.0019.7830.000.000.847-0.0410.000
call7.500.000.750.0020.8170.000.000.843-0.0440.000
put2.501.052.000.0012.3890.000.00-0.144-0.0350.000
put5.003.504.700.0018.6330.000.00-0.153-0.0400.000
put7.505.907.400.0026.7210.000.00-0.157-0.0430.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-06424B5SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-06-168-KCurrent report2026-06-15SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-15SEC
2026-04-244Statement of changes in beneficial ownership of securities2025-01-10SEC
2026-03-114Statement of changes in beneficial ownership of securities2026-03-09SEC
2026-03-114Statement of changes in beneficial ownership of securities2026-03-09SEC
2026-03-034Statement of changes in beneficial ownership of securities2026-03-01SEC
2026-03-034/A2026-02-18SEC
2026-03-034/A2026-02-18SEC
2026-03-034/A2026-02-18SEC
2026-03-034/A2026-02-18SEC
2026-03-034/A2026-02-18SEC
2026-03-034/A2026-02-18SEC
2026-03-034/A2026-02-18SEC
2026-02-273Initial statement of beneficial ownership of securities2026-02-18SEC
2026-02-2610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-268-KCurrent report2026-02-26SEC
2026-02-238-KCurrent report2026-02-18SEC
2026-02-204Statement of changes in beneficial ownership of securities2026-02-18SEC
2026-02-204Statement of changes in beneficial ownership of securities2026-02-18SEC
2026-02-204Statement of changes in beneficial ownership of securities2026-02-18SEC
2026-02-204Statement of changes in beneficial ownership of securities2026-02-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-0340.09K200
2026-020000
2026-010000
2025-12001.03M1
2025-11001.59M3

Institutional holders

Manager% owned
MORGAN STANLEY9.11%
Soleus Capital Management, L.P.7.88%
BlackRock, Inc.5.63%
AQR CAPITAL MANAGEMENT LLC2.34%
VANGUARD CAPITAL MANAGEMENT LLC2.26%
D. E. Shaw & Co., Inc.2.24%
DIMENSIONAL FUND ADVISORS LP1.90%
ACADIAN ASSET MANAGEMENT LLC1.53%
Assenagon Asset Management S.A.1.52%
GEODE CAPITAL MANAGEMENT, LLC1.43%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.55%
iShares Russell 2000 ETF1.40%
VANGUARD EXTENDED MARKET INDEX FUND0.65%
Fidelity Small Cap Index Fund0.59%
iShares Russell 2000 Value ETF0.49%
VANGUARD EXPLORER FUND0.38%
VANGUARD RUSSELL 2000 INDEX FUND0.31%
U.S. Targeted Value Portfolio0.28%
Schwab U.S. Small-Cap ETF0.27%
Schwab Small-Cap Equity Fund0.27%

OakChart. ORGO. Cached 15 minutes.